News Tag: Corporate Information

“We are pleased that all of our tests on the new Dosell have now been successfully completed and look forward to officially presenting the new improved Dosell to all Norwegian municipalities from now on. In the future, the pharmaceutical robot will be a priority product in Hepro's product portfolio. We can now finally start selling, which we look forward to.” Says Geir Tore Jakobsen CEO, Hepro AS

As Dosell is a medical technology product that requires high security and functionality, all of our partners have had to carry out their own internal controls of hardware and software and ensure all integrations and alarm handling. Following the implementation of the first version of Dosell, some technical challenges arose. The problems caused by the challenges have meant that the requirements for testing and quality assurance have become very high in order for the product to be approved. Dosell has now received this quality stamp and now that Hepro has given its approval, the pharmaceutical robot is now approved for the Scandinavian market.

"These tests have taken longer than the forecast. At the same time, we are very happy to work with such serious partners who make solid own checks to ensure all parts. Hepro AS has been a very important partner for us in the development and testing of Dosell 2.0 and it feels fantastic that the product is now secured at all levels.” Says Anders Segerström, CEO of iZafe Group AB.

Questions will be answered by Chief Executive Officer Anders Segerström and published on December 8, 2021 on iZafe Group's investor site under the heading Financial Reports, Investor Questions.
 
Please send your questions to before 10:00 (10 a.m.) CET on December 1, 2021.

Carl-Fredrik has more than 25 years of experience in marketing, communication and digitalization. Among other things, he has worked as Nordic marketing manager for TP-Link Nordic AB and as marketing manager for Sixt rent a car. Carl-Fredrik also has experience from working in growth companies in various stages of development with a focus on, among other things, strategy work and growth. He will also place great emphasis on the Company's IR strategy and in connection with this will also be the contact person for shareholders and investors.

– In our growth journey, it has become natural to create a new position and bring in a senior CMO in the company. With Carl-Fredrik's solid experience in marketing and strategic experience of structured and long-term branding, I am convinced that he will be an important asset in our continued growth journey and management team, says Anders Segerström, CEO of iZafe Group AB.

“With many years of experience working with marketing communication, strategic planning and business development at internationally established companies, I can add expertise to iZafe Group by further developing the business to become a for-profit company. I have at an early stage formed a clear perception of our current situation and see a great potential to together with a very committed organization. I will be able to help increase our brand awareness and demonstrate sales figures, short-term and long-term”, says Carl-Fredrik Bothén, CMO at iZafe Group AB.

Dosell Consumer is a subscription service without binding period or notice period. A subscription for Dosell Consumer can be subscribed and paid for by, for example, the user directly or relatives to the user. After the customer has purchased the hardware for SEK 499 on apoteket.se, the service offers easy registration with payment solutions directly in the app.

”We are very happy that Dosell, as of Monday October 18, will be made available through apoteket.se for anyone to buy, to a relative or to themself. In an early stage we already have about 20 satisfied users that have tested Dosell before launch. We have visited some of them to hear more about how their everyday life has been made simpler and how their safe use of medication has been facilitated by the help of Dosell. See this video where two of our users and their families describe their experiences. Dosell Consumer is a welcome aid in the home for all people who medicate daily.” says Anders Segerström, CEO of iZafe.

About Dosell Consumer
Dosell Consumer and the Dosell app is a simpler version of iZafe´s professional solution and is adjusted to let users and relatives administrate and ensure correct medication without being dependent on healthcare staff. Both versions of the product are compatible with sachets from every supplier on the market.
 
Dosell Consumer will be made available for delivery by Apoteket on Monday October 18, 2021, but it is already possible to register interest to ensure availability when Dosell Consumer is launched.

Every patient that is currently subscribed to Sempli Farma through the current 25 active pharmacies will be offered Dosell by the end of the year. Thus, the Company is optimistic towards the opportunity to begin sales to end-customers in Italy by the end of the year.

“The coming launch of the consumer version in Sweden has provided us with valuable insights towards planning a successful breakthrough in Italy as well. Our expectations for the Italian market are great leading into 2022. It is very positive that Dosell will be able to make use of tax reliefs in conjunction with purchases of digital systems in Italy. This leads the way for a quick and scale-able commercialization in Italy in parallel to Sweden” says Anders Segerström, CEO of iZafe Group.

iZafe has prepared robots in preparation of several pilot studies with Dosell in Italy. After a couple of months of use, Sempli Farma will gather interviews and film reference videos which will be used in communication and be made available through the sales network.

“The market has received the launch of Sempli Farma well and our marketing campaign, where Dosell is presented as the final component, has had a great effect. Dosell is unique on the market and completes our range of services to facilitate safe medication. During the latest nine months we have been contacted by all of the large actors in the healthcare sector (pharmacies and other healthcare networks) and we are currently in many negotiations. We want to believe that we have been a big part of making pharmacies and other stakeholders aware of the importance of dose-packaged medicine in order to facilitate correct medication and strengthen the public health.” says Alessandro Iadecola, CEO of Remedio S.R.L and Sempli Farma.

During the first quarter of 2022, Sempli Farma will begin integrated sales activities and commercialization of Dosell. In connection to this, the product will be offered to the patients that already subscribe to the service Sempli Farma through the 25 connected pharmacies. With the estimated 150 pharmacies that will be added in the next phase, a strong foundation will have been laid for the launch in Italy. A successful start of sales implies that iZafe can look ahead towards further international expansion in Spain and Portugal, which are the targetable markets that follow after Italy. Currently, there are no direct competitors to Dosell, either in Italy, Spain or Portugal.

About Sempli Farma by Remedio S.R.L
The Italian healthcare company Remedia has built a network of strategically chosen partners in Italy in order to find a combination of different medicine administration aids and distribution channels that enable elders to live at home for a longer period of time. In contrast to Sweden, the possibility to use sachets has not been available in Italy. This has inspired Remedio to launch this concept in Italy and develop the complete solution Sempli Farma.

Sempli Farma is a service that connects the treating doctor with the user and their relatives through a closed system of medical dispensing. The healthcare concept has a goal of reducing the cost of healthcare and making the Italian healthcare system more efficient. Dosell will be the ultimate component by delivering the sachets while simultaneously controlling medication and gathering statistics.

Sempli Farma has grown during 2020 and 2021 through a capital raise of EUR 300,000. The organization has gained strength with the addition of a clinical engineer, a sales manager that works to create an external sales network, as well as a marketing and communication department.

The scope of protection in question refers to the pharmaceutical robot Dosell and its services. The application has been submitted for protection in key markets that iZafe has identified and wherein iZafe has seen great demand for Dosell. These markets are Europe, the United States, Russia and China. The extensive geographic patent protection is sought in order to prepare for the international expansion that is planned to be executed after the ongoing rights issue.

“The pharmaceutical robot Dosell is perceived as simple and easy to use, both for the user and the caregiver, and this combined with an affordable price has led to us seeing a great potential internationally for both our corporate version and the consumer version. It is therefore crucial to work strategically with our intangible assets as we expand the business.” says Anders Segerström, CEO of iZafe Group.

Furthermore, the Company has filed an international patent application regarding advanced, digitalized and smart functions that provide a more intelligent and adaptable version of Dosell.

By using sensors and other digital care equipment in the home and regularly measuring patient-specific data, the system provides even safer medication for patients. The international patent application enables iZafe to obtain patents in more than 150 countries. The current patent application creates a strong basis for patent protection in selected markets, including Sweden, the whole of Europe, Asia and the United States.

Today, the Company announces that Göran Hermansson and Anders Segerström will subscribe for a total of 458,000 units, corresponding to SEK 687,000.00 SEK. Göran Hermansson subscribes for 324,667 units, corresponding to SEK 487,000.50. Anders Segerström subscribes for 133,333 units, corresponding to SEK 199,999.50, in addition to his existing subscription commitment of SEK 315,046.50. Anders Segerström has received unit rights from Göran Hermansson in order to subscribe with preferential rights. This means that the Board of Directors and management have subscribed for a total of 876,149 units, corresponding to SEK 1,314,223.50 in the ongoing Rights Issue.

Subscription commitment and underwriting commitments
The Rights Issue is already covered to approximately 18 percent through subscription commitments and to approximately 82 percent through underwriting commitments. In total, 100 percent of the Rights Issue is thus covered by subscription commitments and underwriting commitments before Anders Segerström and Göran Hermansson’s additional subscriptions.

The subscription commitments have been made by a number of existing shareholders in the Company (by, among others, Chairman of the Board Joachim Källsholm, Board member Richard Wolff, CEO Anders Segerström, CFO Ida Almgren, Sales Manager Tobias Johansson, former Chairman of the Board Carl Johan Merner and the Company’s founders Göran Sjönell and Sten Röing) as well as external investors.

Important dates for the Rights Issue
Trading in unit rights on Nasdaq First North Premier Growth Market: October 4 – October 13, 2021
Subscription period for the Rights Issue: October 4 – October 18, 2021
Estimated date for publication of issue results: October 21, 2021

Advisors
Mangold Fondkommission AB is the financial advisor to iZafe in connection with the Rights Issue. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the Rights Issue.

During the summer, an exclusive collaboration agreement was signed with Apoteket AB to introduce the pharmaceutical robot Dosell on the consumer market in Sweden. iZafe Group creates, together with Apoteket, an opportunity for all 2.3 million people who take medication daily in Sweden to prioritize proactivity to avoid drug injuries or incorrect medication.

“There is no doubt that drug injuries are a real problem in society. It is still difficult to create insight into the subject as, in the first instance in the event of an injury, one cannot point out that it has arisen because of incorrect medication. Every year, about 35,000 elderly people become so ill from their medicines that they must be hospitalized. It is with pride that we make Dosell available to anyone who takes medication regularly and wants to prevent incorrect medication with a better overview of medicines and increased compliance before an injury occurs. When our ongoing issue is completed, we will be able to scale up production and begin the sales period that we have all been patiently waiting for. The upcoming launch to the public is welcomed in a press conference on October 14 where we invited the media." Says Anders Segerström, CEO of iZafe Group.

About Dosell Consumer
Dosell Consumer is a subscription service that will be available for delivery via Apoteket on October 18, 2021. It is already possible to register an interest in securing availability when Dosell Consumer is launched.

The pharmaceutical insurance, in collaboration with Dagens Medicin, distributes the prize “Golden Pill” every year. The prize is awarded to encourage employees in healthcare, the pharmacy sector and the research world to identify new ways of working and methods in healthcare. New ways of working will contribute to achieving safer medication handling and thus better health for patients.

“Medication errors is today a major problem in society. Our statistically significant market survey shows that 87 percent of patients over the age of 60 who are taking several medicines per day put safety first. We want to contribute to safer medication handling with the pharmaceutical robot Dosell. It automates the medication, which means that the individual can manage their medication at home more easily and ensure that you take the right dose at the right time", says Anders Segerström, CEO of iZafe Group.

Dosell Consumer dispenses the right medication packaged in sachets – the right dose at the right time. It also reminds when it's time to take the medicine.

"In addition, relatives do not have to worry. They are notified via SMS when there is a forgotten medicine that must be taken. By automating the process, it will be both easier and safer for everyone involved", concludes Anders Segerström.

About Dosell Consumer

• Dosell Consumer and the Dosell app are a niche version of iZafe Group's professional solution and adapted so that users and relatives can administer medication and ensure the right dosage themselves, without being dependent on healthcare professionals. Both versions of the product are compatible with sachets from all suppliers on the market.
• Dosell Consumer is a subscription service. Subscriptions for Dosell Consumer can be subscribed for and paid for by, for example, relatives on behalf of the user.
• Dosell Consumer will be available for delivery in October 2021, but it is already possible to register an interest for when Dosell Consumer is launched. Click here.